PULMATRIX, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
PULMATRIX, INC. (PULM) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $329.00 thousand for the 12-month period ending 2024-12-31, per its S-4/A filed 2026-09-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-09-17
- PULMATRIX, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- PULMATRIX, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- PULMATRIX, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-06-30 was $114.00K, a 72.06% decline year-over-year.
- PULMATRIX, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-03-31 was $215.00K, a 41.73% decline year-over-year.
- PULMATRIX, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.34M, a 3.04% decline from fiscal 2022.
- PULMATRIX, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.38M, a 29.62% increase from fiscal 2021.
- PULMATRIX, INC. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $1.07M, a 28.86% increase from fiscal 2020.
- PULMATRIX, INC. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $828.00K, a 42.02% increase from fiscal 2019.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-17 | $0.00 derived: sum of 2 quarters · filed 2026-09-17 | $114.00K derived: sum of 3 quarters · filed 2026-09-17 | $329.00K S-4/A · filed 2026-09-17 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-16 | $114.00K derived: sum of 2 quarters · filed 2025-10-16 | $329.00K 10-Q · filed 2025-10-16 | $499.00K derived: sum of 4 quarters · filed 2025-10-16 |
| 2024-06-30 | $114.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $329.00K 10-Q · filed 2025-08-06 | $499.00K derived: sum of 3 quarters · filed 2025-08-06 | $893.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $215.00K 10-Q · filed 2025-05-15 | $385.00K derived: sum of 2 quarters · filed 2025-05-15 | $779.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.19M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $170.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $564.00K derived: sum of 2 quarters · filed 2025-03-21 | $972.00K derived: sum of 3 quarters · filed 2025-03-21 | $1.34M 10-K · filed 2025-03-21 |
| 2023-09-30 | $394.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $802.00K derived: sum of 2 quarters · filed 2024-11-08 | $1.17M 10-Q · filed 2024-11-08 | $1.52M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $408.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $777.00K 10-Q · filed 2024-08-13 | $1.13M derived: sum of 3 quarters · filed 2024-08-13 | $1.47M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $369.00K 10-Q · filed 2024-05-10 | $719.00K derived: sum of 2 quarters · filed 2024-05-10 | $1.07M derived: sum of 3 quarters · filed 2024-05-10 | $1.41M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $350.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $697.00K derived: sum of 2 quarters · filed 2024-03-28 | $1.04M derived: sum of 3 quarters · filed 2024-03-28 | $1.38M 10-K · filed 2024-03-28 |
| 2022-09-30 | $347.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $691.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.03M 10-Q · filed 2023-11-09 | $1.37M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $344.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $686.00K 10-Q · filed 2023-08-10 | $1.02M derived: sum of 3 quarters · filed 2023-08-10 | $1.27M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $342.00K 10-Q · filed 2023-05-12 | $681.00K derived: sum of 2 quarters · filed 2023-05-12 | $928.00K derived: sum of 3 quarters · filed 2023-05-12 | $1.17M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $339.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $586.00K derived: sum of 2 quarters · filed 2023-03-30 | $828.00K derived: sum of 3 quarters · filed 2023-03-30 | $1.07M 10-K · filed 2023-03-30 |
| 2021-09-30 | $247.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $489.00K derived: sum of 2 quarters · filed 2022-11-10 | $728.00K 10-Q · filed 2022-11-10 | $963.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $242.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $481.00K 10-Q · filed 2022-08-10 | $716.00K derived: sum of 3 quarters · filed 2022-08-10 | $950.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $239.00K 10-Q · filed 2022-05-12 | $474.00K derived: sum of 2 quarters · filed 2022-05-12 | $708.00K derived: sum of 3 quarters · filed 2022-05-12 | $914.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $235.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $469.00K derived: sum of 2 quarters · filed 2022-03-29 | $675.00K derived: sum of 3 quarters · filed 2022-03-29 | $828.00K 10-K · filed 2022-03-29 |
| 2020-09-30 | $234.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $440.00K derived: sum of 2 quarters · filed 2021-11-10 | $593.00K 10-Q · filed 2021-11-10 | $743.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $206.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $359.00K 10-Q · filed 2021-08-10 | $509.00K derived: sum of 3 quarters · filed 2021-08-10 | $656.00K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $153.00K 10-Q · filed 2021-05-11 | $303.00K derived: sum of 2 quarters · filed 2021-05-11 | $450.00K derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $297.00K derived: sum of 2 quarters · filed 2021-03-23 | $583.00K 10-K · filed 2021-03-23 | |
| 2019-09-30 | $147.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $433.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $286.00K 10-Q · filed 2020-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |